

112 1st
scope of term.
enabled Sorb-Furcul)

3 administering to the patient a 20(S)-camptothecin for a period of time
4 during which a [pyrimidine base analog] is not being administered to the patient;
5 and in all occurrences no chemotherapeutic agent is administered to the patient.

in all occurrences no chemical formula or specific name provided.

REFUGEE	DATE	NAME	AGE	SEX	STATUS	REMARKS
1	1974	12	12	M	12	12
2	1974	12	12	M	12	12
3	1974	12	12	M	12	12
4	1974	12	12	M	12	12
5	1974	12	12	M	12	12
6	1974	12	12	M	12	12
7	1974	12	12	M	12	12
8	1974	12	12	M	12	12
9	1974	12	12	M	12	12
10	1974	12	12	M	12	12
11	1974	12	12	M	12	12
12	1974	12	12	M	12	12
13	1974	12	12	M	12	12
14	1974	12	12	M	12	12
15	1974	12	12	M	12	12
16	1974	12	12	M	12	12
17	1974	12	12	M	12	12
18	1974	12	12	M	12	12
19	1974	12	12	M	12	12
20	1974	12	12	M	12	12
21	1974	12	12	M	12	12
22	1974	12	12	M	12	12
23	1974	12	12	M	12	12
24	1974	12	12	M	12	12
25	1974	12	12	M	12	12
26	1974	12	12	M	12	12
27	1974	12	12	M	12	12
28	1974	12	12	M	12	12
29	1974	12	12	M	12	12
30	1974	12	12	M	12	12
31	1974	12	12	M	12	12
32	1974	12	12	M	12	12
33	1974	12	12	M	12	12
34	1974	12	12	M	12	12
35	1974	12	12	M	12	12
36	1974	12	12	M	12	12
37	1974	12	12	M	12	12
38	1974	12	12	M	12	12
39	1974	12	12	M	12	12
40	1974	12	12	M	12	12
41	1974	12	12	M	12	12
42	1974	12	12	M	12	12
43	1974	12	12	M	12	12
44	1974	12	12	M	12	12
45	1974	12	12	M	12	12
46	1974	12	12	M	12	12
47	1974	12	12	M	12	12
48	1974	12	12	M	12	12
49	1974	12	12	M	12	12
50	1974	12	12	M	12	12
51	1974	12	12	M	12	12
52	1974	12	12	M	12	12
53	1974	12	12	M	12	12
54	1974	12	12	M	12	12
55	1974	12	12	M	12	12
56	1974	12	12	M	12	12
57	1974	12	12	M	12	12
58	1974	12	12	M	12	12
59	1974	12	12	M	12	12
60	1974	12	12	M	12	12
61	1974	12	12	M	12	12
62	1974	12	12	M	12	12
63	1974	12	12	M	12	12
64	1974	12	12	M	12	12

1 9. A method according to claim 1 wherein the 20(S)-camptothecin

10061974-023102
201209-42618001

2 is administered between 3 and 90 days before the pyrimidine base analog is
3 administered.

1 10. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 4 and 90 days before the pyrimidine base analog is
3 administered.

1 11. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 5 and 90 days before the pyrimidine base analog is
3 administered.

1 12. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 1 day after the pyrimidine base analog is administered.

1 13. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 2 days after the pyrimidine base analog is administered.

1 14. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 3 days after the pyrimidine base analog is administered.

1 15. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 4 days after the pyrimidine base analog is administered.

1 16. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered at least 5 days after the pyrimidine base analog is administered.

1 17. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 1 and 90 days before or after the pyrimidine base analog
3 is administered and is also administered within 1 day of when the pyrimidine base
4 analog is administered.

1 18. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 2 and 90 days before or after the pyrimidine base analog
3 is administered and is also administered within 2 days of when the pyrimidine

10081974-022102
201220-42618001

4 base analog is administered.

1 19. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 3 and 90 days before or after the pyrimidine base analog
3 is administered and is also administered within 3 days of when the pyrimidine
4 base analog is administered.

1 20. A method according to claim 1 wherein the 20(S)-camptothecin
2 is administered between 4 and 90 days before or after the pyrimidine base analog
3 is administered and is also administered within 4 days of when the pyrimidine
4 base analog is administered.

1 21. A method according to claim 1 pancreatic cancer wherein the
2 pyrimidine base analog is a fluorinated analog of a pyrimidine base.

1 22. A method according to claim 1 pancreatic cancer wherein the
2 pyrimidine base analog is a fluorinated analog of uracil.

1 23. A method according to claim 1 wherein the 20(S)-camptothecin
2 is 9-nitro-20(S)-camptothecin.

1 24. A method according to claim 1 wherein the disease associated
2 with undesirable or uncontrolled cell proliferation is cancer.

1 25. A method according to claim 1 wherein [the cancer] is selected
2 from the group consisting of acute myelogenous leukemia, cholangiocarcinoma,
3 chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma,
4 osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung,
5 ovarian, pancreatic, prostate, and stomach cancer.

lacks
clear basis
not seen in
clm 1

1 26. A method according to claim 1 wherein the disease associated
2 with undesirable or uncontrolled cell proliferation is pancreatic cancer.

10084974-03340
20Feb2014 4:26:00 PM

1 27. A method for treating a patient having a disease associated with
2 undesirable or uncontrolled cell proliferation, the method comprising:

3 administering to the patient a 20(S)-camptothecin for a period of time
4 during which a pyrimidine base analog is not present in a pharmacologically
5 active form in the patient's body; and administering a pyrimidine base analog to
6 the patient.

1 28. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 1 day before the pharmacologically active pyrimidine base
3 analog is present in the patient's body.

1 29. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 2 days before the pharmacologically active pyrimidine
3 base analog is present in the patient's body.

1 30. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 3 days before the pharmacologically active pyrimidine
3 base analog is present in the patient's body.

1 31. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 4 days before the pharmacologically active pyrimidine
3 base analog is present in the patient's body.

1 32. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 5 days before the pharmacologically active pyrimidine
3 base analog is present in the patient's body.

1 33. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 1 and 90 days before the pharmacologically active
3 pyrimidine base analog is present in the patient's body.

1 34. A method according to claim 27 wherein the 20(S)-camptothecin

2 is administered between 2 and 90 days before the pharmacologically active
3 pyrimidine base analog is present in the patient's body.

1 35. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 3 and 90 days before the pharmacologically active
3 pyrimidine base analog is present in the patient's body.

1 36. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 4 and 90 days before the period when the
3 pharmacologically active pyrimidine base analog is present in the patient's body.

1 37. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 5 and 90 days before the pharmacologically active
3 pyrimidine base analog is present in the patient's body.

1 38. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 1 day after the pharmacologically active pyrimidine base
3 analog is no longer present in the patient's body.

1 39. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 2 days after the pharmacologically active pyrimidine base
3 analog is no longer present in an active form in the patient's body.

1 40. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 3 days after the pharmacologically active pyrimidine base
3 analog is no longer present in an active form in the patient's body.

1 41. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 4 days after the pharmacologically active pyrimidine base
3 analog is no longer present in an active form in the patient's body.

1 42. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered at least 5 days after the pharmacologically active pyrimidine base

3 analog is no longer present in an active form in the patient's body.

1 43. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 1 and 90 days before or after the pharmacologically
3 active pyrimidine base analog is present in the patient's body and is also
4 administered within 1 day of when the pharmacologically active pyrimidine base
5 analog is present in the patient's body.

1 44. A method according to claim ~~27~~ wherein the 20(S)-camptothecin
2 is administered between 2 and 90 days before or after the pharmacologically
3 active pyrimidine base analog is present in the patient's body and is also
4 administered within 2 days of when the pharmacologically active pyrimidine base
5 analog is present in the patient's body.

1 45. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 3 and 90 days before or after the pharmacologically
3 active pyrimidine base analog is present in the patient's body and is also
4 administered within 3 days of when the pharmacologically active pyrimidine base
5 analog is present in the patient's body.

1 46. A method according to claim ~~27~~ wherein the 20(S)-camptothecin
2 is administered between 4 and 90 days before or after the time when the
3 pharmacologically active pyrimidine base analog is present in the patient's body
4 and is also administered within 4 days of when the pharmacologically active
5 pyrimidine base analog is present in the patient's body.

1 47. A method according to claim 27 wherein the 20(S)-camptothecin
2 is administered between 5 and 90 days before or after the time when the
3 pharmacologically active pyrimidine base analog is present in the patient's body
4 and is also administered within 5 days of when the pharmacologically active
5 pyrimidine base analog is present in the patient's body.

1 48. A method according to claim 27 wherein the pyrimidine base

2 analog is a fluorinated analog of a pyrimidine base.

1 49. A method according to claim 27 wherein the pyrimidine base
2 analog is a fluorinated analog of uracil.

1 50. A method according to claim 27 wherein the 20(S)-camptothecin
2 is 9-nitro-20(S)-camptothecin.

1 51. A method according to claim 27 wherein the disease associated
2 with undesirable or uncontrolled cell proliferation is cancer.

1 52. A method according to claim 27 wherein the cancer is selected
2 from the group consisting of acute myelogenous leukemia, cholangiocarcinoma,
3 chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma,
4 osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung,
5 ovarian, pancreatic, prostate, and stomach cancer.

1 53. A method according to claim ~~27~~ wherein the disease associated
2 with undesirable or uncontrolled cell proliferation is pancreatic cancer.

*lacks clear
anto. basis.
from clm 27.*

10081974 022102
201220 42618001